Back to search results

Hyperpolarized Pyruvate MRI Reproducibility in Solid Tumors

This study is testing a new way to see if a special type of MRI scan, called hyperpolarized MRI, gives consistent results each time it's done for a patient. It uses an imaging agent called Hyperpolarized Pyruvate (DRUG) with the MRI scans. The main goal is to see if these scans can be reproduced reliably. You might be able to join if you are between 21 and 90 years old and have a solid tumor, or a brain lesion highly suspected to be a tumor. Success for this study means showing that the hyperpolarized MRI scans are reproducible. The study is currently unclear about its status and plans to enroll 109 participants.

Study design
This is an interventional study planning to enroll 109 participants. It aims to validate the reproducibility of hyperpolarized MRI scans.
What's involved
You will have two hyperpolarized MRI scans. These scans will be compared with pathological results from surgery.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, validating HP MRI reproducibility, is measured at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02421380

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

Recruiting
NAAges 21–90InterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~109 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:Hyperpolarized Pyruvate

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
validate HP MRI at MSKCC (are the scans able to be reproduced)
Measured over 1 year

Conditions

Malignant Solid Tumors

Explore related trials

Breast CarcinomaMalignant Brain NeoplasmPancreatic CarcinomaProstate CarcinomaSarcomaSolid Neoplasm

Where it's being run

2 sites across 2 states
New Jersey1
New York1

Study leadership

  • Kayvan Keshari, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Kayvan Keshari, PhD
646-888-3631
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with history of histologically-confirmed malignant solid tumor (histology confirmed by MSKCC Department of Pathology.) NOTE: An exception will be made for patients with brain lesions. Patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features will be enrolled, prior to histological confirmation.
Disease measurable or evaluable as defined by RECIST 1.1, a mass of greater than 1cm in the long axis and/or other tumor response criteria from an MSKCC IRB-approved clinical research protocol. NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment.
Negative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards \& Guidelines), from assays obtained \< 2 weeks prior to study enrollment.
This study will include only patients with sarcoma, prostate, breast, brain, metastatic or pancreatic cancer. In the future other patient groups may be included through amendment of this protocol.

Exclusion

Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of \[1-13C\] pyruvate injection)
Breast-feeding
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Hepatic: from assays obtained within 3-4 weeks prior to study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
Bilirubin \> 1.5 x (ULN)
AST/ALT \>2.5 x ULN
Albumin \< 3 g/dl
GGT \> 2.5 x ULN if Alkaline phosphatase \> 2.5 x ULN.
Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min, from assays obtained within 3-4 weeks prior to study enrollment
Acute major illness (e.g., unstable cardiovascular condition, etc.)

What this trial measures

  • validate HP MRI at MSKCC (are the scans able to be reproduced)1 year

    The imaging will include standard T2-weighted, diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and 1H MR spectroscopic imaging, depending on the solid tumor type. This multi-parametric data will be used to delineate the tumor as well as compare to HP MRI.